STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Completed
- Lymphoma, T-Cell
- Lymphoma, Extranodal NK-T-Cell
- Alemtuzumab (Campath)
- EPOCH
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-02-03
Feb 3, 2022U
Completed
- T-Cell Lymphoma Relapsed
- T-Cell Lymphoma Refractory
- London, United KingdomUniversity College London Hospital
2021-10-01
Oct 1, 2021S
Not yet recruiting
- T-cell Lymphoma
- +10 more
- Chicago, IllinoisRush University Medical Center
2021-09-20
Sep 20, 2021N
Completed
- Lymphoma, Large-Cell, Anaplasitc
- +4 more
- Anti-CD30-CAR T cells
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-01-27
Jan 27, 2022N
Not yet recruiting
- Adult T-cell Leukemia/Lymphoma
- +4 more
- CC-486 (5-azacitidine)
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022P
Not yet recruiting
- T-cell Lymphoma
- Tucidinostat, Azacitidine combined with CHOP
- (no location specified)
2021-10-09
Oct 9, 2021L
Active, not recruiting
- T-Cell Lymphoma
- +4 more
- LB1901
- Rochester, Minnesota
- +3 more
2022-02-15
Feb 15, 2022F
Recruiting
- Cutaneous T-cell Lymphoma (CTCL)
- Romidepsin
- Brentuximab vedotin
- Philadelphia, PennsylvaniaFox Chase Cancer Center
2022-02-02
Feb 2, 2022T
Recruiting
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Anti-PD-1 monoclonal antibody
- +2 more
- Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
2021-12-21
Dec 21, 2021M
Recruiting
- CTCL/ Mycosis Fungoides
- Skin suction blistering and skin biopsies
- Vienna, AustriaMedical University of Vienna
2022-04-04
Apr 4, 2022M
Recruiting
- Hematologic Malignancy
- +5 more
- CAR-37 T cells
- Boston, MassachusettsMassachusetts General Hospital Cancer Center
2021-10-28
Oct 28, 2021H
Not yet recruiting
- Peripheral T-Cell Lymphoma
- Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2021-12-26
Dec 26, 2021O
Active, not recruiting
- Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
- Yamagata, JapanYamagata University Hospital
2022-02-21
Feb 21, 2022F
Recruiting
- Peripheral T-cell Lymphoma
- PD-1 antibody+ HDAC inhibitor
- Shanghai, Shanghai, ChinaDongmei Ji
2021-12-03
Dec 3, 2021N
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Not yet recruiting
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- +13 more
- Brentuximab Vedotin
- Pembrolizumab
- Chicago, IllinoisNorthwestern University
2022-01-24
Jan 24, 2022P
Not yet recruiting
- T-cell Non-Hodgkin's Lymphoma
- CD147- CAR T cells
- (no location specified)
2021-08-18
Aug 18, 2021K
Recruiting
- Non Hodgkin Lymphoma (NHL)
- +4 more
- Cincinnati, OhioThe Christ Hospital Cancer Center
2022-02-08
Feb 8, 2022N
Recruiting
- Cutaneous T-Cell Lymphoma
- +3 more
- Romidepsin
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022S
Not yet recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
- (no location specified)
2022-03-18
Mar 18, 2022T
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- Pembrolizumab
- (no location specified)
2022-03-28
Mar 28, 2022C
Recruiting
- Lymphoma, T-Cell, Peripheral
- Osaka, JapanNihon Seimei Hospital
2021-06-01
Jun 1, 2021N
Active, not recruiting
- Peripheral T-cell Lymphoma NOS
- +3 more
- rhIL-15
- Avelumab
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-02-02
Feb 2, 2022C
Terminated
- Cutaneous T-cell Lymphoma (CTCL)
- Stanford, California
- +2 more
2021-12-07
Dec 7, 2021W
Active, not recruiting
- Peripheral T Cell Lymphoma
- Tumor biopsy
- +2 more
- Boston, Massachusetts
- +2 more
2022-02-14
Feb 14, 2022U
Recruiting
- Lymphoma, T-Cell
- Durvalumab
- +3 more
- Charlottesville, VirginiaUniversity of Virginia
2022-03-16
Mar 16, 2022